The changing landscape of biosimilars in rheumatology

Dörner Thomas, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay, Tore K. Kvien, Josef Smolen, Yoshiya Tanaka, Gerd R. Burmester

Research output: Contribution to journalReview article

97 Citations (Scopus)

Abstract

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and healtheconomic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.

Original languageEnglish
Pages (from-to)974-982
Number of pages9
JournalAnnals of the rheumatic diseases
Volume75
Issue number6
DOIs
Publication statusPublished - Jun 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'The changing landscape of biosimilars in rheumatology'. Together they form a unique fingerprint.

  • Cite this

    Thomas, D., Strand, V., Cornes, P., Gonçalves, J., Gulácsi, L., Kay, J., Kvien, T. K., Smolen, J., Tanaka, Y., & Burmester, G. R. (2016). The changing landscape of biosimilars in rheumatology. Annals of the rheumatic diseases, 75(6), 974-982. https://doi.org/10.1136/annrheumdis-2016-209166